Departement of Anesthesiology and Intensive Care
Rome, I, 00161, Italy
NCT Number: NCT00995839
The present study was conducted as a prospective, randomized study to investigate the effects of vasopressin receptor agonists terlipressin and vasopressin on systemic hemodynamics and microcirculation in patients with catecholamine-dependent septic shock.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 2 / Phase 3
Rome, I, 00161, Italy
60 septic shock patients requiring norepinephrine to maintain mean arterial pressure between 65 and 75 mmHg despite adequate volume resuscitation will be enrolled in the study. After an initial hemodynamic resuscitation aimed at achieve a mean arterial pressure between 65 and 75 mmHg and normovolemia, patients will be randomly allocated to be treated with either a) intravenous administration of terlipressin 1 µg∙kg-1∙h-1 for 6 hrs, b) intravenous administration of arginine vasopressin 0.04 UI∙min-1 for 6 hrs, c) intravenous administration of terlipressin bolus dose of 0.5 mg (each n = 20). In all groups open label norepinephrine will be additionally administered to maintain a mean arterial pressure (MAP) between 65 and 75 mmHg, if necessary. Data from right heart catheterization and sublingual microvascular network will be obtained just before randomization (baseline) and then after 6 hours in the vasopressin, terlipressin infusion and terlipressin bolus groups.
The sublingual microvascular network will be studied using the sidestream dark field (SDF)imaging. The device will be applied on the lateral side of the tongue, in an area approximately 2-4 cm from the tip of the tongue. Sequences of 10 secs from eight adjacent areas will be recorded on disk using a personal computer. These sequences will be later analyzed by an investigator blinded to the patient's diagnosis and therapy.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs
Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs
intravenous terlipressin bolus administration at the dose of 0.5 mg
Time frame: over a period of 6 hrs from the time of randomization
Time frame: over a period of 6 from the time of randomization
Time frame: over a period of 6 hrs from the time of randomization
Time frame: over a period of 6 hrs from the time of randomization
Time frame: over a period of 6 hrs from the time of randomization
Time frame: over a period of 6 hrs from the time of randomization
Time frame: over a period of 6 hrs from the time of randomization
University of Roma La Sapienza
Other
Vasopressin Receptor Agonists in Septic Shock: Effects on Microcirculation
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00698048
Diabetes Insipidus, Endocrine System Diseases
Singapore
View Trial DetailsNCT06709573
Diabetes Insipidus, Endocrine System Diseases
Cleveland, Ohio, United States
View Trial DetailsNCT07658014
Cardiovascular Diseases, Infections
Querétaro City, Querétaro, Mexico
View Trial DetailsNCT05900284
Acute Kidney Injury, Female Urogenital Diseases
Pittsburgh, Pennsylvania, United States
View Trial Details